|
SEARCH
|
Research Papers by Venue
AASV 2011
IPVS 2010
AASV 2010
BI Pre-AASV Health Seminar 2010
Leman 2009
AASV 2009
Leman 2008
IPVS 2008
AASV 2008
Leman 2007
AASV 2011
Update on methods for detecting of pathogenic mycoplasma species - Strait (view pdf)
IPVS 2010
Assessing the impact of maternally derived immunity on active immunization of pigs against PCV2 - Baysinger (view pdf)
Profile and agreement of dam and piglet PCV2 IFA titers - Baysinger (view pdf)
Visual-only evaluation of lung lesions as an alternative to palpation at necropsy - Baysinger (view pdf)
AASV 2010
Assessing the impact of maternally derived immunity on active immunization of pigs against PCV2 - Baysinger (view pdf)
Performance benefits resulting from vaccination with Ingelvac CircoFLEX and/or Ingelvac PRRS MLV - Bretey (view pdf)
Visual-only evaluation of lung lesions as an alternative to palpation at necropsy - Taylor (view pdf)
BI Pre-AASV Health Seminar 2010
Performance benefits resulting from vaccination with Ingelvac CircoFLEX and/or Ingelvac PRRS MLV - Bretey (view pdf)
PRRS control: Has it changed post PCV2? - Jones (view pdf)
The quagmire of Enzootic Pneumonia: A view from the trenches - Lowe (view pdf)
Diagnosing clinical disease and subclinical infections in a vaccinated population - Schwartz (view pdf)
Leman 2009
Assessing the impact of maternally derived immunity on active immunization of pigs against PCV2 - Baysinger (view pdf)
Performance benefits resulting from vaccination with Ingelvac CircoFLEX and/or Ingelvac PRRS MLV - Bretey (view pdf)
Differential diagnosis of wasting and respiratory disease in PCV2 vaccinated populations of pigs - Diaz (view pdf)
Correlation between viral load and performance in PCV2 vaccinated or non-vaccinated pigs - Holck (view pdf)
Test characteristics when verifying Mycoplasma hyopneumoniae status in expected negative herds - Johnson (view pdf)
Comparison and economic evaluation of two PCV2 vaccination programs used in France - Lewandowski (view pdf)
Impact of PCV2 viremia in vaccinated and non-vaccinated pigs - Maass (view pdf)
AASV 2009
Efficacy evaluation of a mixed Mycoplasma hyopneumoniae bacterin and a porcine circovirus type 2 vaccine - Eichmeyer (view pdf)
Diagnostic investigation into a reproductive failure associated with porcine parvovirus and porcine circovirus coinfection - McDowell (view pdf)
Field evaluation of Ingelvac CircoFLEX® on growth performance of pigs in a subclinical PCVAD herd - Verbeck (view pdf)
Leman 2008
Efficacy of Ingelvac CircoFLEX® in a herd with subclinical PCVAD - Bretey (view pdf)
A case report on the dynamics of PCVAD in a PCV2-vaccinated herd over time - Cline (view pdf)
PCV2 infection dynamics under field conditions - Diaz (view pdf)
Efficacy of PCV2 vaccination of pigs, dams, or both on pig performance - Edler (view pdf)
Efficacy evaluation of a Mycoplasma hyopneumoniae bacterin in a mixture with a porcine circovirus type 2 vaccine - Eichmeyer (view pdf)
Willingness to approach behavior and feed disappearance of weaned pigs following vaccination with Mycoplasma hyopneumoniae vaccines - Fangman (view pdf)
Rapid onset of protection of two weeks for a novel one dose mycoplasma vaccine - Genzow (view pdf)
Efficacy of Ingelvac CircoFLEX® in face of maternal antibodies in a field trial in France - Grosse Liesner (view pdf)
A comparison of cross-sectional quantitative PCV2 PCR vs. individual animal quantitative PCV2 PCR and associated necropsy findings in 4 cases - Johnson (view pdf)
Performance of conventional health pigs vaccinated with Ingelvac MycoFLEX® or Suvaxyn® RespiFend - Kolb (view pdf)
Effect of PCV2 vaccination on growth performance in a subclinically affected herd - Orveillon (view pdf)
Ingelvac MycoFLEX® provides at least 26 weeks duration of immunity against M. hyopneumoniae - Piontkowski (view pdf)
Vaccination against PCV2 versus tissue homogenate in finishing phase - Ramirez (view pdf)
IPVS 2008
Impact of PCV2 vaccination for controlling Porcine Circovirus Associated Disease in a wean to finish production system - Arnold (view pdf)
An economic analysis of vaccinating pigs with Ingelvac CircoFLEX® to control uncomplicated clinical PCVAD - Cline (view pdf)
Seroprevalence of PCV2 in canadian swine herds - Cunningham (view pdf)
The impact of seroconversion following vaccination on the efficacy of PCV2 vaccination - Desrosiers (view pdf)
Efficacy evaluation of Mycoplasma hyopneumoniae bacterin in a mixture with a porcine circovirus type 2 vaccine - Eichmeyer (view pdf)
Willingness to approach behavior and feed disappearance of weaned pigs following vaccination with mycoplasma vaccines - Fangman (view pdf)
Rapid onset of protection of two weeks for a novel one dose mycoplasma vaccine - Genzow (view pdf)
Comparative performance of barns of pigs vaccinated or not vaccinated with a one-shot PCV2 vaccine - Gillespie (view pdf)
Pork quality implications of PCV2 vaccines under normal conditions of use - Haas (view pdf)
A laboratory evaluation of the comparative injection site tissue reactivity of PCV2 vaccines - Kolb (view pdf)
Effect of PCV2 vaccination on co-infections with porcine reproductive and respiratory syndrome virus and mycoplasma hyorhinis - Mette (view pdf)
Efficacy of a novel one-shot PCV2 vaccine under Japanese field conditions - Miyashita (view pdf)
Efficacy of a novel one-shot PCV2 vaccine in a multi-site production system in Southern Germany - Ritzmann (view pdf)
Lack of interference with maternal immunity and reduction of viremia in PCV2 vaccinated pigs - Ritzmann (view pdf)
Survey of PMWS impact on Brazilian swine companies - Schwartz (view pdf)
Performance of Ingelvac CircoFLEX® vaccinated pigs in a subclinical PCVAD herd - Young (view pdf)
AASV 2008
Impact of Ingelvac CircoFLEX® on PCV2 and porcine circovirus associated disease in a wean-to-finish production system - Arnold (view pdf)
Effects of porcine circovirus type 2 (PCV2) vaccination on mortality and average daily gain - Feldmann (view pdf)
Biologic and economic benefits of controlling subclinical PCVAD with vaccination - King (view pdf)
Comparative safety of PCV2 vaccines under field conditions - Kolb (view pdf)
Leman 2007
Injection site histologic lesions induced by commercial PCV2 piglet vaccines - Christmas (view pdf)
Efficacy of Ingelvac® CircoFLEX™ in pigs vaccinated at 3 or 6 weeks of age in a PRRS and Mycoplasma hyopneumoniae-negative production system - Cline (view pdf)
Results obtained with a novel PCV2 vaccine to protect multiple ages of pigs against PCVAD - Desrosiers (view pdf)
Correlation of serum PCV2 quantitative PCR test results to tissue IHC lesion scores and mortality rates - Diaz (view pdf)
PCV2 infection dynamics in vaccinated versus non-vaccinated groups of pigs from 5 farms - Diaz (view pdf)
The effect of vaccination against PRRSV on quantitative PCV2 PCR results - Genzow (view pdf)
Use of cross-sectional serum quantitative PCR for profiling PCV2 infection dynamics - Gonzalez (view pdf)
Controlling PCV2 and co-infections to reduce the impact of PCVAD in growing pigs - Jones (view pdf)
Comparative performance of barns of pigs vaccinated with Ingelvac CircoFLEX or other PCV2 vaccines - Kolb (view pdf)
An investigation into increased finishing mortality associated with uncomplicated PCV Type 2 infection: A case report - Wilt (view pdf)
Suvaxyn and RespiFend are registered trademarks of Fort Dodge Animal Health.
